TransMedics (TMDX) | Stock Overview & Key Data
TransMedics Performance Comparison
Stock Range
Today's Range
Low: $115.10
High: $119.78
on October 3, 2025
52 Week Range
Low: $55.00
High: $146.98
on January 21, 2025
on October 4, 2024
All-Time High: $177.37 on August 19, 2024
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$4.0B
EPS
1.98
P/E Ratio (TTM)
58.43
Forward P/E
70.12
P/B Ratio
12.38
PEG Ratio
0.33
Div. Yield
N/A
ROE
28.21%
Beta
2.068
Debt to Equity
163.10
Financial Highlights
Profitability
Gross Margin
61.38%
Operating Margin
23.24%
Profit Margin
13.49%
Returns and Earnings
Return on Assets (TTM)
5.80%
Return on Equity (TTM)
28.21%
EBITDA
$110.6M
Net Income (TTM)
$71.7M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$15.80
Quarterly Revenue Growth (YoY)
37.70%
Quarterly Earnings Growth (YoY)
186.30%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| TransMedics TMDX | 4.00B Mid-cap | 1.60% | 8.18% | -10.45% | 63.04% | 73.97% | -16.75% | 180.39% | 764.00% |
| Abbott Laboratories ABT | 234.39B Mega-cap | 0.78% | 1.82% | 0.11% | 2.25% | 18.64% | 19.49% | 32.22% | 22.75% |
| Boston Scientific BSX | 144.20B Large-cap | -0.88% | -9.50% | -6.71% | -1.20% | 8.88% | 15.12% | 144.77% | 136.56% |
| Bio-Rad BIO.B | 8.41B Mid-cap | 0.00% | 15.31% | 13.92% | 17.72% | -12.51% | -14.92% | -36.76% | -46.25% |
| Bio-Rad Laboratories BIO | 8.38B Mid-cap | 12.58% | 6.05% | 21.44% | 30.13% | -6.34% | -11.12% | -28.78% | -46.04% |
| Globus Medical GMED | 8.17B Mid-cap | 8.58% | 2.86% | 2.21% | -16.02% | -26.09% | -14.41% | 1.15% | 12.92% |
Ownership & Short Interest
Insider Ownership
2.96%
Institutional Ownership
110.22%
Shares Short
8M
Short Ratio
8.81
Short % of Shares Outstanding
42.31%
Average 10-Day Volume
716K
Average 90-Day Volume
947K
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is TMDX's 52-week high and low?
- In the last 52 weeks, TransMedics reached a high of $146.98 (on October 4, 2024) and a low of $55.00 (on January 21, 2025).
- What is the market cap and P/E ratio for TMDX?
- Curious about TransMedics's size and valuation? Its market capitalization stands at 4.00B. When it comes to valuation, the P/E ratio (trailing twelve months) is 58.43, and the forward P/E (looking ahead) is 70.12.
- Does TMDX pay dividends? If so, what's the yield?
- As for dividends, TransMedics isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are TransMedics's main competitors or similar companies to consider before investing?
When looking at TransMedics, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Abbott Laboratories
ABT234.39B Healthcare Medical Devices 19.49% 32.22% Boston Scientific
BSX144.20B Healthcare Medical Devices 15.12% 144.77% Bio-Rad
BIO.B8.41B Healthcare Medical Devices -14.92% -36.76% Bio-Rad Laboratories
BIO8.38B Healthcare Medical Devices -11.12% -28.78% Globus Medical
GMED8.17B Healthcare Medical Devices -14.41% 1.15% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for TransMedics Group Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of TransMedics's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 28.21%, the Debt to Equity ratio from the most recent quarter is 163.10, and its Gross Profit Margin stands at 61.38%.
- What is the recent revenue and earnings growth for TMDX?
- Looking at TransMedics's growth, its revenue over the trailing twelve months (TTM) was $531M. Compared to the same quarter last year (YoY), quarterly revenue grew by 37.70%, and quarterly earnings saw a YoY growth of 186.30%.
- How much of TMDX stock is held by insiders and institutions?
- Wondering who owns TransMedics stock? Company insiders (like executives and directors) hold about 2.96% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 110.22%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.